Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 17, 2006 Stephen D. Simpson	Medtronic's Evolutionary Revolution Step by step, Medtronic may change how diabetes is treated.
The Motley Fool November 21, 2007 Rich Smith	Medtronic Motors Ahead Shares of the medical equipment maker soared yesterday and continue to buck the downtrend on Wall Street, in the wake of a fiscal Q2 2008 earnings report that exceeded expectations for both sales and profits.
Chemistry World August 23, 2013 Jessica Cocker	Plant protein regulates diabetes treatment A plant protein has been used to make a new class of glucose-responsive polymer nanogels that could one day negate the need for diabetes patients to constantly monitor their blood glucose levels and inject themselves with insulin.
The Motley Fool October 19, 2007 Brian Lawler	The Exubera Winner In its third-quarter earnings report, Pfizer announces it is surrendering the rights to market inhalable-insulin treatment Exubera to developer Nektar Therapeutics. Investors, take note.
The Motley Fool May 20, 2009 Brian Orelli	Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients.
The Motley Fool November 23, 2010 Jared Cummans	Tuesday's ETF to Watch: Medical Devices Fund (IHI) With Medtronic's earnings report set for today, the iShares Dow Jones U.S. Medical Devices Index Fund should be active in trading.
Chemistry World May 7, 2009 Phillip Broadwith	Polymers release insulin in response to glucose trigger Chinese researchers have developed polymer nanoparticles that can release insulin in response to changes in glucose concentration, creating a potential treatment for diabetes.
The Motley Fool January 13, 2006 Stephen D. Simpson	Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note.
The Motley Fool June 27, 2005 Stephen D. Simpson	Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well.
Chemistry World August 12, 2014 Phillip Broadwith	Sanofi snaps up inhaled insulin license Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialize Mannkind's recently-approved Afrezza inhaled insulin powder for global distribution.
Chemistry World November 22, 2010 Akshat Rathi	Irish drug industry fears bailout tax terms Any increase in Ireland's corporation tax rate as part of a financial bailout could hurt the country's rapidly expanding pharmaceutical industry, currently its largest contributor to corporation tax.
The Motley Fool January 16, 2008 Brian Lawler	Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note.
Chemistry World November 9, 2010 Andrew Turley	Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines.
Chemistry World June 30, 2014 Phillip Broadwith	Inhaled insulin approved in US Mannkind's Affreza is aimed at reducing the need for patients to inject themselves with insulin so frequently.
Chemistry World February 20, 2014 Laura Howes	Brent Sumerlin: Searching for a sweet response Brent Sumerlin is professor of chemistry at the University of Florida in Gainesville, US. His research concerns the identification, synthesis, and characterization of smart polymers for drug delivery.
The Motley Fool July 27, 2007 Rich Duprey	Sniffing Out Bentley's New Patent To succeed in insulin therapy, the generic drugmaker must overcome patent expiration. Investors, take note.
Chemistry World November 8, 2012 Michael Parkin	Nasal gel alternative to insulin injection Scientists has developed a novel insulin delivery system for nasal administration. The study aims to provide an alternative to regular injections through the delivery of insulin via the nasal membrane in the form of a hydrogel.
The Motley Fool May 26, 2005 Stephen D. Simpson	A Second Opinion on Medtronic Medtronic is a growth stalwart, but does valuation properly account for the challenges?
The Motley Fool November 18, 2008 Brian Orelli	No Buffer for Medtronic Even though sales grew for the quarter, investors weren't happy.
The Motley Fool November 18, 2011 Brian Orelli	Medtronic: Cutting Fat and Growing Margins The company announces that it has sold Physio-Control to private-equity fund Bain Capital.
Chemistry World June 22, 2015 Manisha Lalloo	'Smart patch' set to deliver for diabetes patients A research team has created patches that release insulin in response to changes in oxygen brought about by high glucose levels and hope this could lead to a smarter, painless way of treating the disease.
Nurse Practitioner May 2011 Stacey A. Seggelke	Hitting the target for inpatient glycemic management An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes.
The Motley Fool February 22, 2011 Jared Cummans	Tuesday's ETF to Watch: Medical Devices Fund Medtronic reports earnings today.
The Motley Fool March 2, 2005 Bill Mann	How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns.
The Motley Fool February 17, 2009 Brian Orelli	Investors Heart Medtronic The leaner company is more lovable.
The Motley Fool February 17, 2005 Stephen D. Simpson	Is Medtronic's Heartbeat Slowing? Will gradually decelerating growth lead to a multiple contraction on the medical device maker's stock?
The Motley Fool May 19, 2011 Arundhati Parmar	Medtronic, Ford Developing In-Car Diabetes Management System Cars are getting smarter. Imagine if your in-car infotainment system could also alert you when your blood glucose levels were low.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool March 2, 2011	Fool Q&A: Medtronic CFO Gary Ellis The medical-device maker's chief financial officer talks R&D, "One Medtronic," and growth in emerging markets.
Chemistry World August 7, 2012 Anthony King	Irish pharma exports tumble Irish pharma exports to the US declined 30% in the first six months of this year as a clatter of blockbuster drugs made in Ireland, such as Lipitor (atorvastatin), came off patent.
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool June 26, 2009 Brian Orelli	Rumors and Safety Issues -- One Bad Combination There are rumors floating around that a study will show that use of Sanofi's insulin product, Lantus, has an increased risk of cancer.
The Motley Fool July 26, 2007 Ryan Fuhrmann	Zimmer Simmers The maker of hip and knee replacements gets a leg up on the market. Investors, take note.
American Family Physician May 1, 2005	Diabetic Ketoacidosis: What It Is and How to Prevent It An informative patient hand-out on the condition, its causes, triggers, prevention and instructions on what do if the conditions presents.
The Motley Fool January 6, 2005 Stephen D. Simpson	Can Medtronic Still Quicken the Pulse? While increased competition looms for the medical device maker, a shareholder update looks to the past.
The Motley Fool February 20, 2008 Brian Orelli	Medtronic Looks Ahead After a rough second half of last year, Medtronic is leaving its problems behind, and optimistically focusing on the future.
American Family Physician January 1, 2003 Jennifer B. Marks	Perioperative Management of Diabetes Diabetic patients who require surgery present special challenges in perioperative management. Special attention must be paid to prevention and treatment of metabolic derangements.
The Motley Fool February 12, 2004 Jeff Hwang	Rockin' Medtronic The world's premier medical device maker keeps on growing.
The Motley Fool December 29, 2011 Harsh Chauhan	Why Medtronic Is On Course for a Happy New Year Right moves make Medtronic a good investment now.
The Motley Fool June 2, 2004 Brian Gorman	New Injection for Genzyme A partnership with Medtronic bolsters Genzyme's myoblast cell therapy program.
Pharmaceutical Executive October 1, 2005	Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions.
The Motley Fool November 18, 2004 W.D. Crotty	Medtronic Down, Not Out Internal defibrillator maker's earnings growth rate is slowing down, but its future looks healthy.
The Motley Fool May 19, 2009 Brian Orelli	Medtronic Gets Whacked, Seeks Recovery Device Medtronic gets hammered on lackluster guidance.
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
The Motley Fool March 3, 2011 Bryan Hinmon	Medtronic's Moat Is Strengthening Lessons from an interview with Medtronic CFO Gary Ellis.
American Family Physician March 15, 2001 Goutham Rao	Insulin Resistance Syndrome Insulin resistance can be linked to diabetes, hypertension, dyslipidemia, cardiovascular disease and other abnormalities. Because resistance usually develops long before these diseases appear, identifying and treating insulin-resistant patients has potentially great preventive value...
The Motley Fool October 27, 2011 Eric Bleeker	Here's Where Pfizer's Finding Its Growth Let's examine where Pfizer's sales and earnings come from and how its sales abroad have changed over time.
American Family Physician May 1, 2001	Treatment Options for Type 2 Diabetes -- What's Available? What are the different steps in managing my diabetes? What are the different types of medicines used to treat type 2 diabetes and how do they work?
The Motley Fool December 11, 2006 Brian Lawler	Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made.
American Family Physician November 1, 2003 Turok et al.	Management of Gestational Diabetes Mellitus Although the disorder affects approximately 2.5 percent of pregnant women and has been the subject of extensive research, its diagnosis and management continue to be debated.